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Histone methyltransferaseG-gene family that is involved in tumor suppression, DNA repair, cell cycle
regulation, and cellular senescence. Most functions are dependent on the tumor suppressor p53. p33ING2was
also shown to bind to trimethylated lysine 4 of histoneH3. Here, we show that p33ING2 contains a transferable
silencing function, which is independent of p53. p33ING2-mediated gene silencing is resistant to the HDAC-
inhibitor trichostatin A indicating that p33ING2 uses a non-HDAC class I or II pathway for gene repression in
reporter assays. In line with that we show that p33ING2 is associated with histone methyltransferase (HMT)
activity in vitro and in vivo, methylating speciﬁcally histone H3. Interestingly, the speciﬁcity is distinct from the
MeCP2-recruited HMT. Mutation or methylation of lysine 9, a mark well known for repression, abrogates
histone methylation by MeCP2 but not by the p33ING2 complex. Instead, the ING2-associated HMT shows
an increased methylation activity if lysine 9 is methylated. In contrast, mutation or methylation of lysine 4,
a methylation preferentially detected at active genes, led to a reduction of the ING2-associated HMT. Notably,
also p33ING1 recruits HMT activity suggesting a more general biochemical interaction between members of
p33ING family and HMT activity. Deletion analyses revealed that the ING2 C-terminus recruits HMT activity,
which correlates with silencing function.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
ING2 (p33ING2) is a member of the ING tumor suppressor family.
ING1 was initially identiﬁed as a critical cofactor for p53 in cell growth
control [1]. The ING proteins share in their C-termini a plant homeo-
domain (PHD) ﬁnger, a motif common to many chromatin-regulatory
proteins. In human cells, all ﬁve ING proteins have been implicated in
p53 function, control of cell growth/proliferation, and cancer [1]. ING2
negatively regulates cell proliferation through modulation of p53
acetylation in response to DNA damage [1]. In addition, ING2 is in-
volved in nucleotide excision repair via enhancement of global histone
H4 acetylation and chromatin relaxation [2]. The association of ING2
with cancer was reported as loss of heterozygosity in sporadic basal
cell carcinomas that involves the p33ING2 and SAP30 genes [3] and
reduced expression of ING2 in human cutaneous melanomas and
human lung cancer cells [4–6].
All ﬁve ING proteins are key components of speciﬁc HAT/HDAC
multisubunit complexes and therefore critical regulators of the chro-
matin status in vivo. Interestingly, ING1 and ING2 are components of49 3641 934706.
d).
gina Elena Cancer Institute Via
l rights reserved.two related mSin3/HDAC1/2 corepressor complexes suggesting a role
in chromatin compaction and gene silencing [7,8].Whereas ING3, ING4
and ING5 associate with different HAT complexes required for normal
cell cycle progression [7]. A further characteristic is that the expression
of each ING1 or ING2 inhibits cell cycle in primary human cells and
induces premature senescence [8,9].
Interestingly the PHDdomain of ING2was found to bind to the lipid
signaling molecule phosphatidylinositol-5-phosphate (PtdIns(5)P),
which was reported to be critical for ING2 recruitment to chromatin
[10]. In addition, the PHD domain of ING2 was found to bind to the di-
and trimethylated K4 of histone H3 (H3K4me3). Binding of ING2 was
potentiated by hypermethylation of histone bulks with the HMT SET7/
9 [11,12]. Methylation of position-speciﬁc lysine residues in the histone
N-termini is a central modiﬁcation to regulate epigenetic transitions in
chromatin. Each methylatable lysine position can exist in a mono-, di-
or trimethylated state, thereby being potentially marks for the
epigenetic histone coding [13,14]. This suggests that the ING family is
involved in recognition of chromatin marks and in the reading of the
histone code. However, binding of ING2 to histoneH3was suggested to
be independent of PtdIns(5)P-binding [12]. In in vitro binding assays of
methylated histone peptides, the ING2 PHD domain bound most
strongly to H3K4me3, with lower afﬁnity to H3K4me2, and not at all to
numerous other peptides [11,12]. The recruitment to H3K4me3 was
conﬁrmed in vivo and revealed that ING2 recruitment is associated
with repression of a mSin3/HDAC target gene. Thus, it suggests that
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lated H3K4 through its PHD domain, and thereby promotes deacetyla-
tion of nearby acetylated histone residues [11,12].
Our previous data on p33ING1 suggest not only anHDAC-dependent
but also an HDAC-independent pathway of gene repression [8]. The
HDAC-dependent pathway was localized to the N-terminus of ING1,
which was in line with reports of association of ING1-deletion analysis
with SAP30 andwith the SIN3A/HDAC complex [15],whereas theHDAC-
independent pathwaywas localized to the C-terminus of ING1 [8]. ING2
shares high sequence homologies to ING1 in its C-terminus and ac-
cordingly we show here an evidence that also ING2 harbors HDAC-
independent silencing function. The silencing function is mediated in a
p53-independent manner. Since besides histone deacetylation also
histone methylation can regulate gene expression, we addressed the
questionwhether ING2 and ING1 are associatedwithHMTactivity. Here
we describe the association of ING2 with an HMT activity that has
speciﬁcity for histone H3 and H1 in vitro and in vivo. Interestingly, the
PHD ﬁnger itself seems not sufﬁcient for the association of the HMT
activity with ING2. This HMT targets the aa 1–20 of histone H3. The
mostly studied positions K4 and K9 are dispensable but regulate the
methylation efﬁciency of the ING2-associated HMT.
2. Material and methods
2.1. Plasmids
cDNAs of human p33ING1 [8] and p33ING2 (generous gift from Dr. M. Serrano) and
p33ING2 deletions were cloned in frame into the pAB gal1–94 linker [16] or into vectors
harboring the GSTepitope, allowing the expression in bacteria or eukaryotes [17] by use
of standard cloning techniques. The reporter 17mer-6x tkCAT was described elsewhere
[18]. UAS4x-tk-Lucwas kindly provided by S. TenbaumandP. Crespo. The p53 expression
vector was obtained by M. Dobbelstein, and the vector for pCMX-gal-NCoRΔI was
obtained by T. Heinzel [19]. The plasmids pGST-MeCP2 and pGEX-4T-3-AU5-ING2were a
kind gift of A. Bird and M. Serrano, respectively [20]. Site-directed mutagenesis for the
generation of p33ING2 point mutants was performed according to the QuikChange Site-
Directed Mutagenesis Kit protocol (Stratagene). Brieﬂy, the plasmids were ampliﬁed
with overlapping primers containing desired mutations using Pfu Turbo polymerase.
The PCR product was treated with DpnI restriction endonuclease, and the newly
synthesized plasmid containing mutations was then transformed into the DH5α strain.
The mutations and integrity of inserts were veriﬁed by sequencing.
2.2. Cell culture
Thehuman lungcarcinomacell lineH1299,monkeykidneycell lineCV1, immortalized
mouse ﬁbroblasts NIH3T3, transformed mouse ﬁbroblasts Ltk-, human kidney HEK-293
and HEK 293T cells were grown in DMEM supplemented with 10% fetal calf serum, and
penicillin–streptomycin at 37 °C with 5% CO2. HepG2 cells were grown in RPMI sup-
plemented with 10% fetal calf serum, and penicillin–streptomycin at 37 °C with 5% CO2.
Chicken erythrocyte HD3 cells were grown in 8% FCS and 2% chicken serum
supplemented with penicillin–streptomycin at 41 °C with 5% CO2. DEAE-dextran trans-
fectionwas carried out as described elsewhere [21]. Calciumphosphate transfectionwas
performed with minor changes according to [22,23].
Brieﬂy, 6-well dishes were plated 4–12 h prior addition of the DNA transfection-co-
crystals, which were generated by mixing DNA and HEBS (ﬁnal concentration: 0.137 M
NaCl, 6 mM Glucose, 5 mM KCl, 0.7 mM Na2HPO4, 20 mM Hepes pH 7.2) with CaCl2
(ﬁnal concentration: 100 mM) through a 5 second vortexing and 20 minute incubation
step at room temperature. The following amounts of DNA were used: 0.9 µg reporter
and 0.9 µg expression vector for gal-fusions. The reporter pCMV-lacZ (0.2 µg) was used
to standardize for transfection efﬁciency. TSA dissolved in ethanol was added to the
cells at a ﬁnal concentration of 100 ng/ml 16 h after transfection. Cells were harvested
10.5 h after TSA or ethanol treatment.
Each set of experiment was performed at least three times. At least two different
double CsCl-gradient puriﬁed plasmid preparations were used. The error bars represent
the deviation of the mean from two independent transfections. For Trichostatin A
(Biomol) treatment 0.9 µg reporter and 2 µg gal-expression vector were used. After
overnight incubationwith the DNA-CaPO4 crystals cells were washed and incubated for
additional 24 h (CAT-reporter, eGST protein expression), or 48 h (Luc-reporter) prior to
harvest.
2.3. Immune-precipitation
HepG2 cells were lysed with NETN buffer (200 mM NaCl; 20 mM Tris–HCl, pH 8,0;
1 mM EDTA, 0,5% NP-40) and incubated with 5 µl of anti-ING1-antibody, anti-ING2-
antibody or normal rabbit IgG (Santa Cruz Biotechnology) for 3 h and precipitated with
proteinAagarose (Upstate) overnight. Beadswerewashed three timeswith PBScontaining
protease inhibitor cocktail (Roche) and oncewashedwithMAB buffer (20mMKCl, 50mMTris–HCl, pH8.5; 10mMMgCl2,10mMbeta-mercaptoethanol, 250mMsucrose (w/v)). The
immune-precipitates with bound proteins were subjected to the histone methyltransfer-
ase assay (HMT assay). The anti-ING1 or anti-ING2 antibodies were obtained by im-
munization of rabbits with bacterially expressed and puriﬁed p33ING1 or p33ING2, which
was obtained through expression as GST-fusion proteins and subsequent cleavage of the
GST part, separation and isolation of the ING proteins via SDS-PAGE. Immunization was
performed with two rabbits for each p33ING1 or p33ING2 at Eurogentec, Belgium.
2.4. Glutathione S-transferase (GST) pulldowns for histone methyltransferase assay
We expressed GST and GST-fusion proteins in Escherichia coli Bl21 bacteria. The
induction of the protein expression was achieved by the addition of IPTG (0.1 mM,
Applichem) after the bacteria reached OD 0.6. Crude bacterial lysates were produced by
freeze and thaw and soniﬁcation in MTPBS buffer (150 mM NaCl, 16 mM Na2HPO4,
4 mM NaH2PO4, 1 mM PMSF). After the addition of Triton X-100 (1% ﬁnal
concentration), insoluble particles were removed by centrifugation. The GST or GST-
fusion proteins were afﬁnity puriﬁed by binding to glutathione beads (Pharmacia) and
subsequent washing steps with RIPA buffer (150 mM NaCl, 50 mM Tris–HCl (pH 8.0),
0.5% sodium deoxycholate, 1% SDS and 1% NP-40). The GST pulldown assay was
performed by an overnight incubation of the GST proteins prebound to glutathione
beads with HeLa nuclear extract (50 µl, Computer Cell Culture Centre, Mons, Belgium).
The beads were washed 6 times with RIPA buffer and ﬁnally with the buffer used for the
HMT assay.
The pulldown with eukaryotic expressed proteins harboring the GST epitope was
performed by using extracts from transfectedHEK-293 cells. For thewhole cell lysate the
cells were lysed in NETN buffer (100 mM NaCl, 20 mM Tris–HCl (pH 8.0), 1 mM EDTA,
0.5% NP-40) by freeze and thaw. After centrifugation, the extract was directly incubated
with glutathione beads for the puriﬁcation of protein complexes before processing to
histone methyltransferase assay. Nuclear extracts were prepared as described [24].
2.5. Histone methyltransferase assays
The HMT activity was assayed with some modiﬁcations as described elsewhere [20].
Brieﬂy, afﬁnity puriﬁed GST proteins were incubated in MAB buffer (20 mM KCl; 50 mM
Tris–HCl (pH 8.5), 10 mM MgCl2, 10 mM beta-mercaptoethanol, 250 mM sucrose (w/v))
together with 10 µg histones or 5 µg of recombinant H3 (Roche) and 2 µCi S-adenosyl-
[methyl-3H]-methionine (Amersham Biosciences, 60–85 Ci/mmol) as methyl donor. After
4 h at 30 °C the reaction products were separated in an SDS-PAGE and visualized via
ﬂuorography using NAMP100V Amplify™ (Amersham Biosciences). The position of the
radiolabeled histones was identiﬁed by comparison with the Coomassie stained gel. The
assay using peptideswas carried out according to Czermin et al. [25]. ThepeptideswereH3
aa 1–20, containing the ﬁrst amino acids of histone H3 unmodiﬁed, dimethylated at K4,
mutated at K4 (K mutated into L); di- or trimethylated (Peptide Specialty Laboratories) or
mutated (Kmutated to L) atK9and thepeptideH3 aa21–34encompassing theaminoacids
21–34 of histone H3.
3. Results
3.1. p33ING2 harbors p53 independent transcriptional silencing function
To reveal the transcriptional properties of p33ING2 and whether
this is dependenton the tumor suppressor p53weused the established
Gal4 fusion system and generated a fusion of full-length p33ING2with
the DNA binding domain of Gal4 encompassing amino acids 1 to 94,
that lacks the weak transactivation function between amino acid 94
and 147 [16]. We have tested these fusions in various cell types in-
cluding CV1, Ltk-, HEK 293T, HD3 and NIH3T3 cells using the 17mer6x-
tkCAT reporter [26]. Compared to the gal-vector control, p33ING2 is a
potent transcriptional silencer in all cell types tested (Fig. 1). The
silencing function mediated by p33ING2 is dependent on the Gal-
fusion (data not shown). The silencing function was very potent in
293T cells, whereas it was weaker but still prominent in NIH3T3
ﬁbroblasts, CV1, and Ltk- cells.
Because various p33ING2 functions have been shown to be
dependent on the presence of the tumor suppressor p53, we analyzed
whether the silencing function is dependent or can be modulated by
p53. For this purposewe used the p53 negative human lung carcinoma
cell line H1299 [27]. Cotransfection experiments revealed that
p33ING2 exhibits a strong silencing function inH1299 cells, suggesting
that the ING2-mediated repression is not dependent on the presence of
p53 (Fig. 2). In linewith this, cotransfection of p53 did not signiﬁcantly
modulate the silencing function of p33ING2 (Fig. 2A). As a positive
control for p53 action in these cellswe used the humanTERTpromoter,
which is known to be repressed by p53 [28] indicating that p53 is
Fig. 1. The p33ING2 tumor suppressor protein harbors a potent transferable silencing
domain functional in various cell types. The transcriptional properties of p33ING2
were measured with reporter assays in various cell lines cotransfecting an expression
vector encoding Gal-ING2, a fusion of the Gal4 DNA binding domain Gal94 (amino acids
1–94) together with the reporter 17mer6x-tkCAT. As control Gal94 was used. Themean
of the values obtained with Gal94 was set arbitrarily as one and the fold repression by
the p33ING2 fusion is indicated. The datawere normalized to the values obtainedwith
the cotransfected β-galactosidase expression vector (pCMV-lacZ). The error bars in-
dicate the deviation of the mean.
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mechanismof silencingmediated by p33ING2wehaveused theHDAC-
inhibitor TSA. Interestingly, and similar to p33ING1 [8], the silencing
function of p33ING2 is not reduced by TSA treatment of cells (Fig. 2B).
As control, we have used the corepressor fusion Gal-NCoR, which isFig. 2. The p33ING2-mediated silencing function is HDAC-inhibitor-resistant and p53-inde
suppressor p53, was cotransfected with either Gal94 or Gal-p33ING2 together with the report
and the fold repression obtained by the p33ING2 fusion is indicated. Black bars indicate value
values obtained with the empty control vector. The transfection efﬁciency was normalizedwi
HDAC-dependent silencing of p33ING2 by treatment of CV1 cells transfected with full-lengt
arbitrarily as one. As a positive control for TSA-sensitive silencing, Gal-NCoR was used.known to recruit HDAC activity, and accordingly observed that the
NCoR-mediated silencing function was reduced by TSA treatment of
cells. Although the data donot rule out the associationof p33ING2with
HDAC activity they suggest that p33ING2-mediated gene silencing
function is in part independent of classes I and II HDAC activity.
3.2. ING2 recruits HMT activity in vitro and in vivo
To assess the possibility whether the HDAC-independent mechan-
ism of gene silencing is mediated by a p33ING2-associated HMT
activity, bacterially expressed and puriﬁed GST as control or GST-ING2
were incubated with HeLa nuclear extracts. As a positive control
MeCP2 was included, which is known to be associated with an HMT
activity having an enzymatic activity for methylating Lys9 of histone
H3, which is likely to be the H3-K9 speciﬁc SUV39H1 [20]. After
stringent washes, the puriﬁed complexes were incubated with his-
tones as a substrate and S-adenosyl-methyl-3H-methionine (3H-SAM)
as methyldonor. The reaction products were separated in an SDS-
PAGE and visualized via ﬂuorography which showed that p33ING2
was able to copurify a histone methyltransferase that led to a speciﬁc
methylation of histone H3 (Fig. 3A, upper panel), which suggests that
p33ING2 is associated with a histone H3-speciﬁc HMT. GST, as control
did not show an association with an HMT activity. As loading control
for the amounts of bacterially expressed proteins, Coomassie staining
was performed (Fig. 3A, lower panel). To analyze whether histone H3
alone is sufﬁcient for facilitating methylation a similar experiment
was performed using as histones solely histone H3 (Fig. 3B). Com-
pared to the GST negative control background and to the MecP2
positive control in Fig. 3A and B the HMT activity associated with
p33ING2 is signiﬁcantly higher when all four core histones are added.
Interestingly, compared to MeCP2 a much weaker labeling of histone
H3 was detected suggesting that the p33ING2-associated HMT is
more efﬁciently methylating histone H3 in the presence of the other
core histones. It also indicates that MeCP2 is associated with a distinct
HMT.
Since the PHD domain of p33ING1 and p33ING2was shown to bind
to D-myo-phospatidylinositol 5-phosphat (PtdIns(5)P) we addressed
the possibility whether this second messenger might modulate thependent. A) The human lung carcinoma cell line H1299, lacking the functional tumor
er 17mer6x-tkCAT. The mean of the values obtained with Gal94 was set arbitrarily as one
s obtained with cotransfected p53 expression vector (100 ng) and gray bars indicate the
th lacZ values. B) The HDAC-inhibitor Trichostatin A (TSA; 100 ng/ml) was used to test for
h p33ING2 as a Gal94-fusion. Values obtained with Gal94 in the absence of TSA were set
Fig. 3. p33ING2 associates with HMT activity. In vitro HMT assay was performed using bacterially expressed and afﬁnity puriﬁed GST (negative control), GST-ING2, or as a positive
control GST-MeCP2. HeLa nuclear extracts were incubated with these puriﬁed proteins. After stringent washes, the core histones and 3H-SAM were added. Labeling of histones was
visualized by ﬂuorography and the amount of proteins used by Coomassie staining. A) Puriﬁed histones were included in the HMT assay as methylation substrates. The labeled
histone H3 is indicated after ﬂuorography (arrow). The migration of the bacterial GST, GST-ING2 and GST-MeCP2 is indicated with a star. The amount of the core histones added, is
shown in the lower panel after Coomassie staining (small arrows). B) Histone H3 alone was included in a HMT assay in the similar experimental setup as in (A).
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serve a change in the HMT activity in this assay (data not shown).
To determine whether within mammalian cells ING2 associates
with HMT activity, p33ING2 was expressed in mammalian cells as an
epitope tagged fusion protein using a eukaryotic GST fusion [17]. After
afﬁnity puriﬁcation of the GST or the GST-fusion proteins from trans-
fected cells the copuriﬁed proteins were tested for the presence of
histone methyltransferase activity using the histones H1, H2A, H2B,
H3 and H4 as substrate and S-adenosyl-methyl-3H-methionine (3H-
SAM) as methyldonor (Fig. 4A). Similar to the in vitro results with
bacterially puriﬁed proteins the data suggest that p33ING2 asso-Fig. 4. Both p33ING1 and p33ING2 copurify with HMT activity in vivomethylating histones H
puriﬁed and subjected to HMTassay with added histones H1, H2A, H2B, H3 and H4. The amou
stars, the histones by small arrows. Methyl-labeling of the proteins is shown via ﬂuorograph
fusion proteins derived fromwhole cell extract (A) or nuclear extract (B) of transfected HEK2
anti-p33ING2 antibodies were subjected to HMT assay with added histones H1, H2A, H2B, Hciates with an HMT that methylates speciﬁcally histone H3 (Fig. 4A).
Interestingly, we found indications that also histone H1 is a target of
the ING2-associated HMT since the amount of radiolabeled histone is
above background. In addition, p33ING1 was included to determine
whether this ING2-related factor is also associated with an HMT
activity. The obtained data reveal a similar association of p33ING1
with a histone H3 and possibly a histone H1-speciﬁc HMT activity.
Furthermore, nuclear extracts were generated from transfected cells
and subjected to the same HMT assay (Fig. 4B). Also, using nuclear
extracts instead of whole cell extracts the afﬁnity puriﬁed ING1 and
ING2 complexes showed an association with HMT activity.1 and H3. A) and B) Eukaryotic expressed eGST, eGST-ING1, and eGST-ING2 were afﬁnity
nt of proteins used is visualized by Coomassie staining. The GST-fusions are indicated by
y and the labeled histones are indicated by arrows. The afﬁnity puriﬁed eGST or eGST-
93 cells. C) Immune-precipitated (IP) material from HepG2 cells using anti-p33ING1 or
3 and H4.
Fig. 5. The ING2 N-terminus is dispensable for association with HMT activity. Deletion mutants of ING2 were bacterially expressed, and incubated with or without HeLa nuclear
extracts and the histones H1, H2A, H2B, H3 and H4. The employed ING2 deletion mutants are indicated schematically in the top panel with the amino acids expressed and their
migration with a star in the Coomassie stained gel. Control represents GST alone. As a positive control MeCP2 was used. ING2ΔN can signiﬁcantly associate with HMT activity.
Fig. 6. The ING2 domain associated with HMT activity harbors repression function. The
transcriptional silencing functions of various ING2 deletions and single amino acid
exchange mutants within the PHD ﬁnger shown to have reduced or lack binding to the
histone mark H3K3me3 [11] were compared using Gal-fusions that were tested in
reporter assays in HEK293 cells. The values obtained with Gal94 were arbitrarily set as
one and the silencing of promoter activity is plotted as fold repression (see legend Fig.1).
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activity, co-immune-precipitation experiments were performed using
p33ING1 and p33ING2 speciﬁc antibodies and HepG2 cells. The
immune-precipitated proteins were subjected to the HMT assay as
described above. Compared to the control (IgG) both the endogenous
ING1 and ING2 complexes were able to methylate speciﬁcally histone
H3 (Fig. 4C). Interestingly, a weaker labeled band corresponding to
histone H1 was also detected, which was clearly above background
(Fig. 4C) suggesting that also histone H1 could be a target of the ING-
associated HMT.
Taken together, the data indicate that both ING1 and ING2 associate
with an HMT activity in vivo, which is speciﬁc for histone H3 and
histone H1.
3.3. The p33ING2 N-terminus is dispensable for the association with the
HMT activity
To testwhich region of p33ING2 is associatedwith the HMTactivity
a battery of different ING2 deletions was generated (Fig. 5) and
employed for the in vitro HMT assay. Methylation of histone H3 was
observed with ING2 and the ING2 deletion encompassing the amino
acids 77–280 whereas other deletion mutants of ING2 had strongly
reduced association of HMT activity. As controls, GST alone or ING2
without incubation of nuclear extract were included. Also, the amount
of used proteins is indicated in the Coomassie stained gel. Thus, the
methylation of histone H3 and H1 was also facilitated by the N-
terminal deletion mutant of ING2. In contrast to ING2, MeCP2
associates with a histone H3 but not histone H1 speciﬁc HMT activity.
This indicates that also histone H1, albeit much weaker, is a target for
methylation. Therefore, the data suggest that the N-terminus of
p33ING2 is not required for association with the HMT activity.
To assess whether the association of HMT activity correlates with
the ability of transcriptional regulation, the silencing function of full-length ING2, the ING2 N-terminus alone and the N-terminal deletion
mutantwere analyzed. Expressionvectors for Gal, Gal-ING2, Gal-ING2-
NandGal-ING2ΔNwere tested in both CV1 andHEK293 cells.Whereas
Gal-ING2 exhibits silencing function, the N-terminus encompassing
the ﬁrst 75 amino acids failed to repress in both cell lines (Fig. 6 and
data not shown). In contrast, although slightly weaker, the N-terminal
deletion of ING2was able to exhibit silencing function (Fig. 6). Further,
the deletion mutants of ING2, ING2-M and ING2-C, were employed
that did not reveal an association with the HMT activity. In line with
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harbors the PHD ﬁnger indicating that the PHD ﬁngermay notmediate
gene silencing. To further verify whether the binding activity to
the histone mark H3K4me3 through the PHD ﬁnger is required for
silencing function, we have tested three point mutants of ING2 in the
PHD ﬁnger that were previously shown to have a strongly reduced or
lost binding activity to this histone mark [11]. To ensure that the
mutations would only interfere with the C-terminal silencing function
we have used the ING2-ΔN mutant. Interestingly, the silencing
function of the mutants was retained and showed a similar repression
function compared to the wild-type sequence (Fig. 6) suggesting that
the binding to this histone mark is independent from the C-terminal
ING2-mediated silencing function.
These data suggest that the region of p33ING2 associating with
HMT activity correlates with strong silencing function.
3.4. The ING2-associated HMT activity methylates histone H3 aa 1–20
distinct from lysines 4 and 9
To gain insight of the speciﬁcity of the ING2-associated HMT
activity, we focused on the histone H3 speciﬁcity of the ING2-asso-
ciated HMT activity and employed peptides of histone H3 in the HMT
assay. Amino acid positionswell known to play a role in transcriptional
repression in their methylated state are lysine 9 and lysine 27 [29].
Therefore, to narrow down the methylation position targeted by the
ING2-associated HMT, we used peptides encompassing the aa 1–20
and 21–34, respectively (Fig. 7). Bacterially expressed GST alone, GST-
ING2, or GST-MeCP2 fusion proteins were afﬁnity puriﬁed, incubated
with nuclear HeLa cell extract and after stringent washes, histone
peptides corresponding to the histoneH3 tail aa 1–20 or aa 21–34were
added. After the enzymatic reactionwith labeled 3H-SAMas a cofactor,
the methylation of the histone peptides was quantiﬁed with a
scintillation counter (Fig. 7). Compared to afﬁnity puriﬁed GST alone,
the GST-ING2 fusion was able to copurify an HMT that is able to
methylate the histone peptide aa 1–20 but not containing the aa 21–34
(Fig. 7A). This does not exclude that the ING-associated HMT might
methylate residues beyond aa 34 of histone H3. MeCP2 served as a
positive control known to be associated with an HMT activity that
methylates lysine 9 of histone H3 [20]. In line with this, using GST-
MeCP2 no signiﬁcant HMT activity was observed with the peptide aa
21–34 as substrate. As a positive control, crude HeLa nuclear extracts
were incubated with the histone peptide revealing the presence of
HMT activity in the extracts and the functioning of the peptide as
substrate. Thus, the data indicate that ING2 is associated with an HMT
activity that is speciﬁcally methylating histone H3 aa 1–20.
The lysines well known to bemethylated in this region are the lysine
4 and lysine 9. To test whether these are targeted formethylation by the
ING2-associated HMT activity, peptides with K4 or K9 modiﬁcations
were employed (Fig. 7B). Therefore, we analyzed ﬁrst K9 known to be
associated with gene silencing using peptides harboring di- or
trimethylated K9 in histone H3 aa 1–20. Interestingly, the ING2-
associated HMT activity facilitated the methylation of these peptides.
In contrast, no signiﬁcant labeling compared to the GST control alone
was obtained with MeCP2 suggesting that MeCP2 associated HMT
activity is inhibited by dimethylated K9 in histone H3 whereas that of
ING2 not, neither by di- nor trimethylated K9. In contrast, the labeling of
the trimethylated peptide by the ING2 complex is more efﬁcient
compared to the unmodiﬁed peptide (Fig. 7B).Fig. 7. The ING2-associated HMTactivitymethylates histone H3 aa 1–20 distinct from lysines
HeLa nuclear extract and after stringent washes employed in the HMTassay similarly as show
of the histone peptides was measured with a scintillation counter and the counts per minute
counts. As positive control crude nuclear extracts were directly added to the histone peptide
21–34 of the unmodiﬁed histone H3were used. B) Lysine 9 speciﬁcity of the ING2-associated
aa 1–20 at lysine 9. C) Lysine 4 speciﬁcity of the ING2-associated HMT activity was analyzed b
aa 1–20.Next, a point mutation of K9 to leucinewas analyzed (aa 1–20 K9L).
As expected, the HMT activity associated with MeCP2 was unable to
label the histone peptide whereas that of ING2 was still able and
furthermore more efﬁciently compared to the wild-type peptide. This
suggests that the target methylation site of the HMT that is associated
with ING2 is distinct from lysine 9 of histone H3.
Next, we addressed the inﬂuence of K4 methylation of histone H3
(Fig. 7C). Interestingly, employing dimethylated K4 of histone H3
peptides resulted in signiﬁcant reduction of labeling by both the
MeCP2 and ING2-associated HMT activity. Instead, using HeLa nuclear
extract as positive control a labeling of this peptide was yielded.
This suggests that dimethylation of K4 prevents to a great extent
methylation of histone H3 aa 1–20 by the ING2-associated HMT. To
analyze the role of K4 inmore detail, a mutation of K4 to leucine (aa 1–
20 K4L)was used (Fig. 7C). As control, GST-MeCP2 and nuclear extracts
were included. Compared to the background obtained with the nega-
tive control GSTalone, signiﬁcant labelingwas obtainedwithGST-ING2
and GST-MeCP2, which indicates that mutation of this site reduces but
does not abrogate the ING2- or MeCP2-associated HMT activity on
histone H3.
Taken together, MeCP2 is associated with an HMT activity that has
K9 of histone H3 as a target site, but its associated HMT activity is
negatively inﬂuenced by dimethylation of K4. In contrast, the HMT
activity associated with ING2 is not abrogated by mutation or
trimethylation of K9 but is enhanced in its activity. Interestingly, this
activity is negatively inﬂuenced by dimethylation and mutation of K4.
This suggests a cross-talk between K4 and K9 modiﬁcation status for
the ING2-associated HMT activity. Furthermore, it suggests that ING2
is associated with a novel HMT activity.
4. Discussion
In the present study we could demonstrate that p33ING2 harbors a
transcriptional silencing function that is independent of p53 and
HDAC's classes I and II. The data obtained suggest that ING2 is
associatedwith an HMTactivity that is speciﬁc for the histone H3 aa 1–
20.We also observed a speciﬁc but weakermethylation for histone H1.
The HMT activity associated with ING2 requires the ING2 C-terminus
harboring the PHD ﬁnger. However, deletion analysis and point mu-
tants indicate that the silencing function is independent of the binding
activity of the PHD ﬁnger to the histone mark H3K4me3 suggesting
that the two functions are separable. The methylation site targeted by
the ING2-associatedHMTseems to be neither the prominent K4 nor K9
site of histone H3. Thus, the well-known HMT's transferring transcrip-
tional repression like Suv39h1, ESET, G9A or EZH2, which are targeting
K9 or K27 respectively, can therefore be excluded as potential ING2
interaction partners. Interestingly, the activity of the ING2-associated
HMT is inﬂuenced by themodiﬁcation status of K4 andK9.Methylation
of lysine 4, a modiﬁcation associated with euchromatic genomic
regions [30,31] led to a decrease, whereas methylation of K9, well
known to play an important role in transcriptional repression, led to an
increase in methylation activity. Besides lysine 4 and lysine 9 there are
5 positions that could theoretically be methylated by the ING2
complex. Potential methylation sites of the ﬁrst 20 amino acids of
histone H3 are three arginines and 2 further lysine, K14 and K18.
Methylation of arginines was reported to play a role in transcriptional
activation [32–34] except for PRMT5 thatmethylates both arginine 8 of
histone H3 and arginine 3 of histone H4, which is associated with gene4 and 9. Bacterially expressed and puriﬁed GST-ING2 or GST-MeCP2were incubatedwith
n in Fig. 3 except not histones but the indicated histone peptides were used. The labeling
(cpm) are indicated. GST alone was used as negative control indicating the background
s in the presence of 3H-SAM. A) Histone H3 peptides corresponding to the aa 1–20 or aa
HMTactivity was analyzed by employing di-, trimethylated, or mutated (K9L) histone H3
y using modiﬁcation or mutation (K4L) of lysine 4 of histone H3 peptide encompassing
1680 F. Goeman et al. / Biochimica et Biophysica Acta 1783 (2008) 1673–1680repression [35]. However, since we have not observed methylation of
histone H4 the data suggest that PRMT5 is not the candidate HMT of
the ING complex.
Acetylation of lysine 14 like lysine 9 is tightly connected with an
active transcriptional status [13,36]. Therefore, a methylation of this
position would counteract an acetylation and consequently an active
state. Zhang et al. found this position to be methylated [37] but so far
no HMT responsible for this methylation was identiﬁed. A further
characterization of the p33ING2-associated HMT could therefore lead
to the identiﬁcation of a novel type of HMT transferring transcrip-
tional repression with a new speciﬁcity.
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